Beurs.nl monitor iconMarkt Monitor
  • AEX -36,13 841,29 -4,12%
  • DE40 -1.075,67 20.641,72 -4,95%
  • US500^ 0,00 5.075,84 0,00%
  • US30^ 0,00 38.321,70 0,00%
  • EUR/USD -0,01 1,0960 -0,84%
  • WTI 0,00 62,71 0,00%
  • Gold spot -75,23 3.038,43 -2,42%

Esperite (voorheen Cryo Save) Terug naar discussie overzicht

NEWS : Esperite upgrade Tranquility

257 Posts
Pagina: «« 1 ... 4 5 6 7 8 ... 13 »» | Laatste | Omlaag ↓
  1. twopence 19 mei 2015 09:28
    Ik denk dat we blij kunnen zijn als het niet lager sluit dan 5 % onder de slotkoers van gisteren. Het lijkt me duidelijk dat hier het paard voor de koerier uit is gegaan.
  2. stormvogel 19 mei 2015 10:05
    Tranquility to the most complete CE-IVD fetal DNA NIPT test.

    TRANQUILITY tops the trisomies detection market by combining the technologies of IONA and InKaryo, the recently acquired company now part of the ESPERITE group. TRANQUILITY's entire testing process for trisomies (sample collection, preparation, sequencing, bioinformatics analysis and report) is compliant with the European In Vitro Diagnostics Medical Devices Directive 98/79/EC and has been certified by an independent body -UL International. TRANQUILITY, the only CE-IVD certified genetic test for trisomies 21, 18 and 13 that provides, sexual aneuploidies, microdeletions and fetal sex detection, now ready for mass market.

    Succesfully launched in several countries, Tranquility already contributes to the positive trend of growth that GENOMA is recording in the Group's key markets: Spain, Italy, Hungary, Serbia, etc.

    The NIPT test is more sensitive and specific than the current combined test, providing accurate and reliable results to pregnant women. The benefits of NIPT are a higher detection rate and lower false positive rate than existing screening tests, giving pregnant women, their families and their doctors greater confidence in the result. This further reduces the need for unnecessary invasive follow-up tests and the associated anxiety and stress.

    Genoma targets a population of 10 million newborns per year in Europe and The Middle East.

    www.stockhouse.com/news/press-release...

    Collaboration agreement with Premaitha Health for provision NIPT in Europe.

    GENOMA signed an agreement with Premaitha Health plc ("Premaitha", AIM: NIPT) under which GENOMA will have the right to use Premaitha's CE-IVD IONA® test for its non-invasive prenatal testing (NIPT) TRANQUILITY®. Access to Premaitha's test will allow GENOMA to apply the CE-IVD marking to its NIPT for trisomies 21, 18 and 13.
  3. twopence 19 mei 2015 11:07
    Vooralsnog helpt dit de koers niet. Dus geduld is wat we hier nu moeten opbergen. Het zal zeker nog verder omhoog gaan, maar nu nog even niet denk ik. Maar wie ben ik.
  4. [verwijderd] 19 mei 2015 11:12
    morgen weer een paar centjes eraf, overmorgen weer.
    het is nu gewoon weer wachten op een PB
    zo is het steeds gegaan met dit aandeel en gaat nu weer gebeuren.
  5. [verwijderd] 19 mei 2015 11:58
    Van dit soort stukjes wordt ik echt blij. Er zit nog veel meer in het vat voor Esperite beleggers:

    Frédéric Amar, Chief Executive officer, commented:

    "Esperite is best-positioned to capitalize on the current confluence of demographic and economic indicators: higher purchasing power, augmented healthcare needs and a health-conscious aging population. Esperite elaborates and makes its mass products affordable to society and national health systems, profiting from the incremental processing and sequencing capacity to produce higher throughput at lower costs.

    Esperite combines cutting-edge technologies and scientific knowledge on its automated processes to deliver the vital genetic information that enables preventive and personalized medicine. Esperite's products and services empower doctors and families to take a proactive and most effective approach to their health".

    ESPERITE WILL DISCLOSE MORE ON ITS STRATEGY DURING THE AGM CONVENED ON JUNE 17TH 2015 IN AMSTERDAM.
  6. twopence 19 mei 2015 12:27
    quote:

    Krasje schreef op 19 mei 2015 11:45:

    Vreemd, want de prognose lijkt goed te zijn.
    Dat is ook zo maar de koersstijging op het voor bericht was lijkt mij wat overspannen..
257 Posts
Pagina: «« 1 ... 4 5 6 7 8 ... 13 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beurs.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.141
AB InBev 2 5.541
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 52.328
ABO-Group 1 25
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.909
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 193
Adecco 1 1
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.871
Aedifica 3 927
Aegon 3.258 323.134
AFC Ajax 538 7.092
Affimed NV 2 6.305
ageas 5.844 109.907
Agfa-Gevaert 14 2.070
Ahold 3.538 74.353
Air France - KLM 1.025 35.304
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.056
Alfen 16 25.370
Allfunds Group 4 1.520
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 426
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.826
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 244.126
AMG 972 134.570
AMS 3 73
Amsterdam Commodities 305 6.747
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 497
Antonov 22.632 153.605
Aperam 92 15.089
Apollo Alternative Assets 1 17
Apple 5 386
Arcadis 252 8.807
Arcelor Mittal 2.035 321.036
Archos 1 1
Arcona Property Fund 1 287
arGEN-X 17 10.362
Aroundtown SA 1 221
Arrowhead Research 5 9.751
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.663
ASML 1.766 110.925
ASR Nederland 21 4.517
ATAI Life Sciences 1 7
Atenor Group 1 522
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 14.216
Axsome Therapeutics 1 177
Azelis Group 1 67
Azerion 7 3.449